title: Influence of imatinib at a low dose and sildenafil on pulmonary hypertension in rats.
abstract: The study investigates whether combination therapy of sildenafil with imatinib at a low dose (20 mg/kg) further ameliorates pulmonary hypertension (PH) in rats. The effects on right ventricle pressure (RVP), and right ventricle hypertrophy (RVH) were assessed in experimental monocrotaline (MCT)-induced pulmonary hypertension. Combined therapy reversed the MCT-induced increase in RVP more than each drug alone and decreased RV hypertrophy (RV/LV+ S ratio), significantly. Such additive effects toward improvement of PH may result from both pharmacodynamic and pharmacokinetic drug-drug interactions, however, further studies are required to assess its mechanistic background.
authors.forename: M
authors.initials: M
authors.lastname: Jasińska-Stroschein
authors.forename: J
authors.initials: J
authors.lastname: Owczarek
authors.forename: K
authors.initials: K
authors.lastname: Cicha
authors.forename: D
authors.initials: D
authors.lastname: Orszulak-Michalak
mesh_terms: D000818:Animals; D001794:Blood Pressure / Q000187:drug effects; D006339:Heart Rate / Q000187:drug effects; D006976:Hypertension, Pulmonary / Q000139:chemically induced / Q000188:drug therapy* / Q000503:physiopathology; D017380:Hypertrophy, Right Ventricular / Q000517:prevention & control; D000068877:Imatinib Mesylate / Q000627:therapeutic use*; D008297:Male; D016686:Monocrotaline; D047428:Protein Kinase Inhibitors / Q000627:therapeutic use*; D051381:Rats; D017208:Rats, Wistar; D000068677:Sildenafil Citrate / Q000627:therapeutic use*; D014665:Vasodilator Agents / Q000627:therapeutic use*
chemical_list: D047428:Protein Kinase Inhibitors; D014665:Vasodilator Agents; D016686:Monocrotaline; D000068877:Imatinib Mesylate; D000068677:Sildenafil Citrate